Lupin Delivers Operationally Strong Q3, Sustenance Remains Key: Dolat Capital 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Lupin Ltd.’s Ebitda margin recovered to 18% in Q3 (versus our expectation of 17%) post a full blown quarter sales of gAlbuterol in the U.S.

U.S. sales at $188 million (up $8 million QoQ) was largely led by gAlbuterol (gained approximately 8% Rx share) offsetting the lower seasonality in base portfolio.

The company remains on track to ramp up Proair volumes to more than 10 million units in the next few months.

We expect absence of Perrigo to persist in the near term providing further opportunity to gain market share.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.